Compare

Zai Lab Ltd vs Arrowhead Pharmaceuticals, Inc. vs Nature's Sunshine Products Inc vs Travere Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearZai Lab Ltd
ZLAB
Arrowhead Pharmaceuticals, Inc.
ARWR
Nature's Sunshine Products Inc
NATR
Travere Therapeutics, Inc.
TVTX
Year ended2025-12-312026-09-302025-12-312025-12-31
Revenue$457.18M$450.82M$480.14M$490.73M
Revenue growth (YoY)+15.0%-45.6%+5.7%+110.5%
Gross margin58.3% (computed)n/a72.4%n/a
Operating margin-50.2%-156.9%5.2%-12.8%
Net margin-38.4%-159.1%4.3%-5.2%
Net income-$175.54M-$717.13M$20.45M-$25.55M
EPS (Diluted)-$0.16-$5.11$1.06-$0.29
Operating cash flow-$150.79M-$271.95M$35.32M$37.78M
Free cash flow-$158.89M-$283.94M$28.84Mn/a
Cash & equivalents$679.57Mn/a$93.89M$93.03M
Total assets$1.17B$1.74B$261.15M$605.19M
Total liabilities$456.88Mn/a$99.59M$490.36M
Shareholders' equity$715.50M$50.50M$161.55M$114.83M
Return on year-end equity-24.5%n/m12.7%-22.2%
Shares outstanding1.11B141.29M17.51M90.92M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearZai Lab LtdArrowhead Pharmaceuticals, Inc.Nature's Sunshine Products IncTravere Therapeutics, Inc.
Latest$457.18M
Ended 2025-12-31
$450.82M
Ended 2026-09-30
$480.14M
Ended 2025-12-31
$490.73M
Ended 2025-12-31
1 year earlier$397.61M
Ended 2024-12-31
$829.45M
Ended 2025-09-30
$454.36M
Ended 2024-12-31
$233.18M
Ended 2024-12-31
2 years earlier$266.72M
Ended 2023-12-31
$3.55M
Ended 2024-09-30
$445.32M
Ended 2023-12-31
$145.24M
Ended 2023-12-31
3 years earlier$212.67M
Ended 2022-12-31
$240.74M
Ended 2023-09-30
$421.91M
Ended 2022-12-31
$109.46M
Ended 2022-12-31
4 years earlier$144.10M
Ended 2021-12-31
$243.23M
Ended 2022-09-30
$444.08M
Ended 2021-12-31
$131.84M
Ended 2021-12-31